GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

SLM · Dec 31, 2024

SLM Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001628280-25-006776Bank
Sequential deposit growth35thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.deposits

-1.76% · CORE · VALID

Net-income growth50thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

4.63% · CORE · VALID

Interest-income growth40thOwn-history percentile · N=20
Evidence method

Yoy · gp.financial.interest_income

1.03% · CORE · VALID

Cash and equivalents70thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$4.7B · CORE · VALID

Sequential loan growth55thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.loans

2.16% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History43 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Decreased
Previous
3.38%
Current
-1.76%
Delta
-5.14%
Earnings Growth Increased
Previous
-253.76%
Current
4.63%
Delta
258.39%
Interest Income Growth Increased
Previous
0.06%
Current
1.03%
Delta
0.97%
Liquidity Increased
Previous
$4.5B
Current
$4.7B
Delta
$210.8M
Loan Growth Decreased
Previous
8.17%
Current
2.16%
Delta
-6.00%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.